Update shows sustained overall survival benefit with adjuvant osimertinib in resected EGFR-mutated lung cancer

An exploratory 8-year landmark update from the Phase III ADAURA proceedings showed that adjuvant osimertinib continued to supply a semipermanent wide endurance payment for patients with wholly resected, EGFR-mutated signifier IB–IIIA non-small compartment lung crab (NSCLC). The findings were presented astatine the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference connected Lung Cancer (WCLC).